NCT00099593|CompletedPhase 2
Immunization Against Tumor Cells in Sezary Syndrome
Phase II Evaluation of Immunization Against Tumor Cells in Subjects With Sezary Syndrome Using Autologous Mature Dendritic Cells
Loading search results
Phase II Evaluation of Immunization Against Tumor Cells in Subjects With Sezary Syndrome Using Autologous Mature Dendritic Cells
Sponsor study identifier
Secondary identifiers
interventional
17
1 country
1
Study Start
September 2004
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
September 2007
Actual (reported)This research is being done to look at the safety and value of a vaccine for a cancer found in the blood and skin known as Cutaneous T-cell lymphoma (CTCL) and Sezary Syndrome. In the laboratory, researches found that special white blood cells, called dendritic cells (DCs), are able to stimulate the immune system (groups of cells that protect the body from germs and diseases) in a way that helps your body fight cancer. Autologous (from your own body) DCs will be prepared (mixed together) in the laboratory with your cancer cell (Sezary cells) to allow your DCs to pick up parts of your Sezary cells to make the vaccine for you.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 2007
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 2004
Date type not reportedThis date has not been verified as actual or estimated.
December 17, 2004
Actual (reported)December 20, 2004
Actual (reported)September 2007
Actual (reported)Clinical response (clearance of skin lesions, clinical and radiographic improvement in lymphadenopathy)
Biological response
Survival
Activities of daily living
Quality of Life
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
University of Pittsburgh Medical Center, Department of Dermatology
Pittsburgh, Pennsylvania, 15213, United States
Larisa J. Geskin, M.D.
University of Pittsburgh
First Submitted
December 17, 2004
First Posted
December 20, 2004
Study Start
September 2004
Date type not reportedThis date has not been verified as actual or estimated.
Study Completion
September 2007
Actual (reported)Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.
Contact the study team to confirm eligibility.
Last Updated
March 25, 2015
Record last verified: 2006-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: